Drug intelligence / Profile preview

WM-P1

Development stage: Preclinical
Lead developer: Wellmarker Bio

Overview

WM-P1 is an investigational drug candidate being developed by Wellmarker Bio for the treatment of liver cancer. It is part of a pipeline that includes other agents targeting various solid tumors, such as colon, breast, and non-small cell lung cancer. Specific details regarding its mechanism of action, molecular modality (e.g., small molecule or antibody), and precise biological target have not been disclosed in publicly available sources as of June 2025. The drug is referenced alongside other Wellmarker Bio assets in preclinical or early clinical development for oncology indications[6].

Beyond the preview

Go deeper on WM-P1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WM-P1.

Explore the full profile